ArticleStem cell research & therapy2025
Platelet-rich plasma enhances local homing of umbilical cord-derived mesenchymal stem cells to articular cartilage by increasing the quantity and activation of integrin ꞵ1.
Article in Stem cell research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Recent trends in modified mesenchymal stromal cells: engineering approaches and international regulatory landscape.Molecular biology reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundEnhancing mesenchymal stem cells (MSCs) engraftment at the degenerative cartilage is important to increase the therapeutic effect of cartilage regeneration. Platelet-rich plasma (PRP) is known to have anti-inflammatory and anabolic effects for the treatment of osteoarthritis and has been reported to be commonly used with MSCs. However, little is known about the effects of PRP on MSCs adhesion to cartilage extracellular matrix (ECM). The purpose of this study was to investigate how PRP pre-conditioning enhances MSC adhesion to cartilage ECM and improves the efficacy of MSCs in promoting cartilage regeneration in a rat osteochondral defect model.
methodIn vitro adhesion of umbilical cord-derived MSCs (UC MSCs) to collagens, fibronectin, and hyaluronic acid and to osteochondral explants was measured with or without PRP pre-conditioning using a cell viability assay. The mRNA expression of integrin subunits and the activity level of integrin ꞵ1 (ITGB1) were evaluated using RT-PCR and western blot, respectively. After establishing an osteochondral defect in the femoral trochlea in Sprague-Dawley rats (n = 26), UC MSCs with PRP were locally injected into the defect. After 4 weeks, macroscopic and histological evaluations were performed using ICRS and O'Driscoll scoring systems.
resultsPRP significantly increased the adhesion of MSCs to collagens, fibronectin, and degenerative osteochondral explants, and this effect was inhibited primarily by ITGB1. Pre-conditioning of MSCs with PRP altered ITGB1 into an active form without cell-to-ECM interaction. Pre-conditioning UC MSCs and type II collagen with PRP prior to adhesion significantly enhanced their adhesion by 4.1-fold compared to the control. In histological evaluation, the O'Driscoll scores of UC MSCs (11.56 ± 0.53, p < .001) and UC MSCs + PRP group (14.13 ± 0.53, p < .001) were significantly higher than the control group (4.40 ± 0.82). PRP as a vehicle of MSCs showed a higher O'Driscoll score than MSCs with saline by 1.2-fold (p = .035).
conclusionThis suggests that pre-conditioning MSCs and cartilage ECM with PRP synergistically enhanced MSC adhesion to the cartilage ECM by increasing both the quantity and activation of ITGB1 in MSCs, thereby enhancing the therapeutic effects of MSCs on articular cartilage regeneration in a rat osteochondral defect model.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.